Archives
-
ddhCTP: Mechanism and Antiviral Research Use
2026-09-04
ddhCTP, also called 3ʹ-deoxy-3′,4′-didehydro-CTP, is a viperin-derived antiviral nucleotide analog that can terminate RNA synthesis by selected viral RNA-dependent RNA polymerases. Its defined molecular identity, water solubility, cold-storage requirement, and reported flavivirus activity make it useful for mechanistic assays and antiviral drug development.
-
ddhCTP: Mechanism and Antiviral Research Use
2026-09-04
ddhCTP, also called 3ʹ-deoxy-3′,4′-didehydro-CTP, is a viperin-generated nucleotide analog that can terminate RNA synthesis by selected viral RNA-dependent RNA polymerases. Its defined mechanism and reported activity against flaviviruses make it a useful RNA virus replication inhibitor for antiviral research, while coronavirus data show that activity is virus-specific.
-
ZCL278: From Cdc42 Activity to Causal Assays
2026-09-03
ZCL278 is a selective Cdc42 inhibitor for connecting GTPase activity with cell behavior and pathway-specific phenotypes. This article presents an assay-centered framework that distinguishes direct target engagement from downstream effects, using kidney fibrosis research as a translational case study.
-
(+)-Bicuculline: Protocol and QC Guide
2026-09-03
This guide explains how to prepare, store, and quality-check (+)-Bicuculline for controlled neuroscience experiments involving GABAA receptor antagonism and related synaptic readouts. It is intended for research workflows only and should not be used to support clinical, diagnostic, or therapeutic conclusions.
-
N1-Methyl-Pseudouridine-5'-Triphosphate Workflow
2026-09-02
Build more stable, translation-ready RNA by integrating N1-Methylpseudo-UTP into a controlled in vitro transcription workflow. The approach is especially useful for comparing RNA chemistry, delivery, and antigen–adjuvant design in mRNA vaccine development without confusing formulation effects with transcript quality.
-
CTP Solution for p21 mRNA Workflows
2026-09-02
CTP Solution (100 mM) provides a defined Cytidine-5'-triphosphate input for IVT mRNA, RNA amplification, and related biochemical assays. This article connects nucleotide quality control with the preclinical p21 mRNA–LNP bladder cancer workflow while separating published findings from practical optimization recommendations.
-
HyperScribe T7 High Yield Cy3 RNA Kit
2026-09-01
The HyperScribe T7 High Yield Cy3 RNA Labeling Kit enables flexible fluorescent probe synthesis for RNA localization and hybridization assays. This guide connects Cy3-UTP incorporation with the MALAT1–miR-125b–STAT3 findings in sepsis research and shows how probe design affects assay interpretation.
-
RBMS1 Loss Enables PD-L1 Blockade in TNBC
2026-09-01
A 2022 Cell Death & Differentiation study identified the RNA-binding protein RBMS1 as a regulator of immune-cold triple-negative breast cancer through post-transcriptional control of PD-L1 stability. The work connects RBMS1 depletion to destabilization of B4GALT1 mRNA, reduced PD-L1 glycosylation, enhanced PD-L1 degradation, and stronger responses to T-cell-based immunotherapy.
-
CTP Solution for p21 mRNA-LNP Workflows
2026-08-31
A practical guide to using high-purity CTP in IVT mRNA workflows that support localized p21 mRNA–LNP research. It connects nucleotide quality, reaction control, RNA QC, and troubleshooting to the bladder cancer delivery strategy reported in the reference study.
-
p21 mRNA-LNP Delivery for Bladder Cancer
2026-08-31
The reference study develops a localized, nonviral tumor suppressor replacement strategy in which chemically modified p21 mRNA is packaged in lipid nanoparticles and administered intravesically. Its preclinical data connect restoration of nuclear p21 with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced growth of orthotopic bladder tumors, while also highlighting the importance of localized mRNA delivery and reproducible upstream RNA synthesis.
-
WAY-100635: 5-HT1A Antagonist Research Guide
2026-08-30
WAY-100635 is a potent, selective, and silent serotonin 5-HT1A receptor antagonist for serotonin receptor antagonist research and neuroscience receptor pharmacology. Its competitive binding profile and functional antagonism support receptor-binding, behavioral, and translational imaging workflows, but the compound is not itself a validated clinical imaging agent or therapy.
-
CTP Solution for p21 mRNA-LNP Workflows
2026-08-29
CTP Solution (100 mM) provides a defined, nuclease-free Cytidine-5'-triphosphate input for IVT mRNA and RNA amplification workflows. This practical guide connects reagent handling and quality control with the localized p21 mRNA-LNP strategy reported for bladder cancer, while separating established findings from bench-level recommendations.
-
CBD, Orofacial Pain, and Affective Deficits
2026-08-28
This 2026 study shows that cannabidiol (CBD) can reduce inflammatory pain while also improving pain-related emotional and cognitive abnormalities in mice. Its integrated behavioral, molecular, endocannabinoid, and circuit-level design links peripheral CB2-associated actions, central CB1 signaling, and altered serotonin dynamics without establishing a direct 5-HT1A receptor mechanism.
-
N1-Methyl-Pseudouridine-5'-Triphosphate in mRNA IVT
2026-08-28
N1-Methyl-Pseudouridine-5'-Triphosphate helps researchers produce IVT RNA designed for improved stability and translational performance. This guide connects nucleotide selection to practical mRNA workflows, including localized p21 mRNA delivery studies, assay controls, and troubleshooting decisions.
-
R2 Retrotransposon Insertions and DNA Repair Pathways
2026-08-27
McIntyre, Horton, and Collins identify distinct human DNA-repair routes that convert R2 retrotransposon–initiated first-strand cDNA into intact or truncated genomic insertions. Using the PRINT system, the study connects insertion architecture and junction signatures to Polymerase θ end-joining, Shieldin/CST-Polα-primase fill-in synthesis, and CtIP-MRN-dependent strand annealing, clarifying a previously unresolved stage of target-primed reverse transcription.